Salud financiera de hoja de balance de Quanterix

Salud financiera controles de criterios 6/6

Quanterix tiene un patrimonio de los accionistas total de $346.9M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $425.0M y $78.1M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$321.32m
Patrimonio	US$346.93m
Total pasivo	US$78.08m
Activos totales	US$425.01m

Actualizaciones recientes sobre salud financiera

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Apr 05

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Oct 12

Recent updates

Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues

Apr 14

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Apr 05

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Mar 03

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Oct 12

We're Not Very Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Rate

Jun 12

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Feb 10

Quanterix Corporation: Selling For Less Than Cash Value

Sep 28

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Sep 23

Quanterix stock gains after insider buys reported by CEO and CFO

Aug 17

We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely

Mar 28

Is Quanterix (NASDAQ:QTRX) A Risky Investment?

Feb 21

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($378.4M) de QTRX superan a sus pasivos a corto plazo ($38.5M).

Pasivo a largo plazo: Los activos a corto plazo de QTRX ($378.4M) superan a sus pasivos a largo plazo ($39.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: QTRX está libre de deudas.

Reducción de la deuda: QTRX no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 18.6%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: QTRX tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: QTRX dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 8.3% cada año

Salud financiera de hoja de balance de Quanterix

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

We're Not Very Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Rate

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely

Recent updates

Quanterix Corporation to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 9.7% to US$29.80

New minor risk - Shareholder dilution

Quanterix Corporation, Annual General Meeting, Jun 03, 2024

Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues

Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Quanterix Corporation Receives Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: EPS misses analyst expectations

Quanterix Corporation Provides Earnings Guidance for the Year 2024

Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023

Quanterix Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 11% to US$33.25

New minor risk - Shareholder dilution

Quanterix Corporation Revises Earnings Guidance for the 2023

Quanterix Corporation Revises Earnings Guidance for the 2023

New major risk - Revenue and earnings growth

Quanterix Corporation to Report Q3, 2023 Results on Nov 06, 2023

Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Price target increased by 9.7% to US$31.00

Director recently bought US$502k worth of stock

High number of new directors

Quanterix Corporation Appoints William (Bill) P. Donnelly to its Board of Directors

Consensus estimates of losses per share improve by 20%

Quanterix Corporation Announces Michael Doyle Cease Serving as Treasurer, Effective August 21, 2023

Quanterix Corporation Provides Earnings Guidance for the Full-Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation to Report Q2, 2023 Results on Aug 08, 2023

Quanterix Corporation Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer's Disease in Patients

We're Not Very Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Rate

Consensus estimates of losses per share improve by 12%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 11% to US$15.25

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Quanterix Corporation Appoints Brian Blaser to Board of Directors

Quanterix Corporation Simoa Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease Conference

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Quanterix Corporation Reports Goodwill Impairment for the Third Quarter Ended September 30, 2022

Quanterix Corporation to Report Q3, 2022 Results on Nov 08, 2022

Quanterix Corporation: Selling For Less Than Cash Value

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Quanterix Corporation Appoints Daniel Pikora as Chief Operating Officer

Quanterix stock gains after insider buys reported by CEO and CFO

Consensus forecasts updated

Independent Director recently bought US$2.0m worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Quanterix Corporation Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors

Quanterix Corporation to Report Q2, 2022 Results on Aug 08, 2022

Price target decreased to US$34.50

Quanterix Corporation Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S

Quanterix Corporation Announces Resignation of John Fry as General Counsel and Secretary, Effective August 12, 2022

President recently sold US$85k worth of stock

Quanterix Announces Appointment of Karen A. Flynn to Board of Directors

Quanterix Corporation Announces Resignation of Dawn Mattoon as Senior Vice President, Diagnostics, Effective July 10, 2022

Consensus forecasts updated

Price target decreased to US$45.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation to Report Q1, 2022 Results on May 10, 2022

Quanterix Corporation, Annual General Meeting, Jun 23, 2022

Quanterix Corporation Grants Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis

Quanterix Corporation announced that it has received funding from Alzheimers Drug Discovery Foundation

We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely

Consensus forecasts updated

Quanterix Announces Executive Leadership Succession Plan, Effective April 25, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind